What is Currently the Best for Adenocarcinoma without Driver Mutation?

Tuberculosis and Respiratory Diseases

article

Cheol-Kyu Park¹  In-Jae Oh¹  Young-Chul Kim¹ 

[1] Department of Internal Medicine, Chonnam National University Medical School

DOI  :  10.4046/trd.2018.0024

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

Since the discovery of driver mutations or actionable alterations in several genes such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), the management paradigms of non-small cell lung cancer (NSCLC) have changed dramatically1 . However, in global guidelines2 , platinum-based chemotherapy remains a standard of care for patients who do not harbor driver mutations. Among several regimens of platinum doublet chemotherapy, the pemetrexed/cisplatin combination confers better overall survival compared to gemcitabine/cisplatin in patients with adenocarcinoma histology3 . In the PARAMOUNT study, continuation maintenance therapy with pemetrexed is an effective and well-tolerated treatment for patients with advanced non-squamous NSCLC with good performance status who have not progressed after 4 cycles of pemetrexed/cisplatin4,5. Moreover, pemetrexed became one of the most frequently administered cytotoxic chemotherapeutic agents for treating stage IV non-squamous NSCLC.

【 授权许可】

CC BY-NC